| Drug Type Small molecule drug | 
| Synonyms Binaprofen, Felbinac, 万舒安 | 
| Target | 
| Action inhibitors | 
| Mechanism COX inhibitors(Cyclooxygenases inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Inactive Organization- | 
| Drug Highest PhaseNDA/BLA | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC18H23NO5 | 
| InChIKeySWKYVGAYFCGGRP-UHFFFAOYSA-N | 
| CAS Registry935886-64-9 | 
| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | - | - | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Pain, Postoperative | NDA/BLA | China  | 10 Jul 2024 | |
| Pain, Postoperative | NDA/BLA | China  | 10 Jul 2024 | |
| Pain | NDA/BLA | - | - | |
| Low Back Pain | Phase 3 | China  | 10 May 2021 | |
| Low Back Pain | Phase 3 | China  | 10 May 2021 | |
| Nephrolithiasis | Phase 3 | China  | 10 May 2021 | |
| Nephrolithiasis | Phase 3 | China  | 10 May 2021 | |
| Neuralgia | Phase 3 | China  | 10 May 2021 | |
| Neuralgia | Phase 3 | China  | 10 May 2021 | |
| Cancer Pain | Phase 3 | China  | 08 Apr 2021 | 





